

**S708A CLEANSING NOTICE**

**Sydney:** AI & Medical Technology company Echo IQ (the Company) (ASX:EIQ) issued a total of 2,053,330 fully paid ordinary shares (shares) on 25 November 2022.

1,540,000 shares have been issued pursuant to the settlement of the shares to HeartX. 513,330 shares have been issued for the services provided by HealthTech Arkansas and MedAxiom in lieu of cash.

The Company has issued all shares utilising its existing placement capacity under Listing Rule (LR) 7.1.

The Shares are part of a class of securities quoted on the Australian Securities Exchange Limited (ASX).

The Company gives this notice pursuant to Section 708A(5)(e) of the Corporations Act 2001. The Shares were issued without disclosure to the investors under Part 6D.2, in reliance on Section 708A(5) of the Corporations Act 2001. The Company, as at the date of this notice, has complied with:

- the provisions of Chapter 2M of the Corporations Act 2001; and
- Section 674 of the Corporations Act 2001.

There is no excluded information as at the date of this notice, for the purposes of Sections 708A(7) and (8) of the Corporations Act 2001.

- ENDS -

**Authorised for release by the Board of Directors of Echo IQ Limited.**

**Media Enquiries:**

Philip Woolff, Chief Operating Officer

[philip.woolff@echoiq.ai](mailto:philip.woolff@echoiq.ai) / [marketing@echoiq.ai](mailto:marketing@echoiq.ai) / +61 (0)490 030 620

**Investor Enquiries:**

Andrew Grover, Executive Chair

[Andrew.grover@echoiq.ai](mailto:Andrew.grover@echoiq.ai) / [investor@echoiq.ai](mailto:investor@echoiq.ai)

**ABOUT ECHO IQ**

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.